Published in J Pharmacol Exp Ther on September 09, 2008
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release (2013) 1.46
Intraperitoneal therapy for peritoneal cancer. Future Oncol (2010) 1.25
Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J (2010) 1.25
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev (2011) 1.11
F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res (2010) 1.09
Drug delivery systems for intraperitoneal therapy. Pharm Res (2010) 1.06
Intratumoral drug delivery with nanoparticulate carriers. Pharm Res (2011) 0.95
Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. J Control Release (2011) 0.93
Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors. J Control Release (2014) 0.91
Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. Nanomedicine (Lond) (2011) 0.91
Entering the era of nanoscience: time to be so small. J Biomed Nanotechnol (2013) 0.89
Therapeutic strategies based on polymeric microparticles. J Biomed Biotechnol (2012) 0.83
Multiscale tumor spatiokinetic model for intraperitoneal therapy. AAPS J (2014) 0.82
Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. ScientificWorldJournal (2013) 0.81
Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. Adv Drug Deliv Rev (2015) 0.79
When 1+1>2: Nanostructured composites for hard tissue engineering applications. Mater Sci Eng C Mater Biol Appl (2015) 0.78
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. J Control Release (2015) 0.77
Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opin Drug Deliv (2014) 0.77
Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model. Drug Deliv Transl Res (2014) 0.77
Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer. AAPS J (2015) 0.77
Improved i.p. drug delivery with bioadhesive nanoparticles. Proc Natl Acad Sci U S A (2016) 0.76
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials (2016) 0.76
Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals. J Control Release (2016) 0.75
Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. PeerJ (2015) 0.75
Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy. Expert Opin Drug Deliv (2016) 0.75
Liposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo Molecules. Biomacromolecules (2016) 0.75
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 13.63
Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev (1997) 5.73
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 5.56
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 2.10
Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 1.88
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol (1992) 1.54
Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther (2007) 1.44
Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mater Res A (2006) 1.44
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol (2006) 1.42
Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther (1999) 1.32
Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mater Res (1985) 1.21
Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther (2001) 1.20
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res (1987) 1.16
Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol (1990) 1.15
Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol (1991) 1.09
Effects of carrier on disposition and antitumor activity of intraperitoneal Paclitaxel. Pharm Res (2007) 1.09
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol (1998) 1.09
Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol (2000) 1.07
Time- and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci (2001) 1.06
Pharmacokinetic principles of locoregional chemotherapy. Cancer Surv (1993) 1.01
Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res (2003) 1.00
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol (1993) 0.99
Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs (2001) 0.94
Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am (2003) 0.92
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 0.89
Intraperitoneal chemotherapy for ovarian cancer. N Engl J Med (2006) 0.88
Intraperitoneal chemotherapy with melphalan. Ann Intern Med (1984) 0.86
Pharmacodynamics of doxorubicin in human prostate tumors. Clin Cancer Res (1998) 0.85
Pharmacodynamics of taxol in human head and neck tumors. Cancer Res (1996) 0.84
Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res (1991) 0.84
Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switching. J Chromatogr B Biomed Appl (1995) 0.83
Paclitaxel-loaded crosslinked hyaluronic acid films for the prevention of postsurgical adhesions. Pharm Res (2002) 0.82
Pharmacologic data and technical feasibility of intraperitoneal doxorubicin administration. Tumori (1985) 0.81
Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer. Eur J Gynaecol Oncol (1998) 0.80
Affinity of intraperitoneally injected activated carbon particles adsorbing mitomycin C to tumor surface of Yoshida sarcoma. Anticancer Drug Des (1990) 0.79
Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Cancer Res (1988) 0.79
Intraperitoneal mitomycin C in the treatment of peritoneal carcinomatosis following second-look surgery. Semin Oncol (1988) 0.79
Serous surface carcinoma of the peritoneum: useful role of cytology in differential diagnosis and follow-up. Acta Cytol (1996) 0.78
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 18.34
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Unsupervised pattern discovery in human chromatin structure through genomic segmentation. Nat Methods (2012) 4.89
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol (2013) 4.20
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature (2002) 3.67
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol (2009) 3.58
Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol Cell Biol (2004) 3.57
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res (2003) 3.09
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol (2012) 2.98
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol (2013) 2.94
Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res (2013) 2.55
Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res (2004) 2.37
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis (2008) 2.31
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
An ancient transcription factor initiates the burst of piRNA production during early meiosis in mouse testes. Mol Cell (2013) 2.23
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
Genomic binding profiles of functionally distinct RNA polymerase III transcription complexes in human cells. Nat Struct Mol Biol (2010) 2.15
Functional analysis of transcription factor binding sites in human promoters. Genome Biol (2012) 2.12
Role for activating transcription factor 3 in stress-induced beta-cell apoptosis. Mol Cell Biol (2004) 2.10
Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A (2013) 2.09
Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc Natl Acad Sci U S A (2010) 2.06
Drug delivery and transport to solid tumors. Pharm Res (2003) 2.05
Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes (2003) 2.05
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol (2011) 2.02
Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics (2008) 1.99
Central nervous system imprinting of the G protein G(s)alpha and its role in metabolic regulation. Cell Metab (2009) 1.98
Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol (2006) 1.98
A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res (2007) 1.96
Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis (2005) 1.89
Development of heart failure in chronic hypertensive Dahl rats: focus on heart failure with preserved ejection fraction. Hypertension (2006) 1.87
PPARG, KCNJ11, CDKAL1, CDKN2A-CDKN2B, IDE-KIF11-HHEX, IGF2BP2 and SLC30A8 are associated with type 2 diabetes in a Chinese population. PLoS One (2009) 1.86
Toll-like receptor 3 mediates establishment of an antiviral state against hepatitis C virus in hepatoma cells. J Virol (2009) 1.85
Epigenetic signatures of autism: trimethylated H3K4 landscapes in prefrontal neurons. Arch Gen Psychiatry (2011) 1.81
Heterotypic piRNA Ping-Pong requires qin, a protein with both E3 ligase and Tudor domains. Mol Cell (2011) 1.79
PKA phosphorylation activates the calcium release channel (ryanodine receptor) in skeletal muscle: defective regulation in heart failure. J Cell Biol (2003) 1.78
Organization of the Caenorhabditis elegans small non-coding transcriptome: genomic features, biogenesis, and expression. Genome Res (2005) 1.77
Adaptation to P element transposon invasion in Drosophila melanogaster. Cell (2011) 1.76
Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem (2002) 1.73
A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause (2003) 1.71
High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol (2012) 1.70
Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther (2007) 1.70
NONCODE v2.0: decoding the non-coding. Nucleic Acids Res (2007) 1.69
Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J (2005) 1.67
Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol (2010) 1.64
The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol (2007) 1.63
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
MR diffusion tensor imaging study of postinfarct myocardium structural remodeling in a porcine model. Magn Reson Med (2007) 1.57
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol (2012) 1.57
Surgical treatment strategies in chronic pancreatitis: a meta-analysis. Arch Surg (2012) 1.54
ECM1 controls T(H)2 cell egress from lymph nodes through re-expression of S1P(1). Nat Immunol (2011) 1.54
Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization. Cardiovasc Res (2004) 1.53
UAP56 couples piRNA clusters to the perinuclear transposon silencing machinery. Cell (2012) 1.53
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain (2007) 1.53
Synthesizing a novel genetic sequential logic circuit: a push-on push-off switch. Mol Syst Biol (2010) 1.52
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res (2006) 1.52
Single-beat estimation of end-diastolic pressure-volume relationship: a novel method with potential for noninvasive application. Am J Physiol Heart Circ Physiol (2006) 1.50
Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release (2013) 1.46
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Short- and long-term outcomes after laparoscopic and open hepatectomy for hepatocellular carcinoma: a global systematic review and meta-analysis. Ann Surg Oncol (2012) 1.46
Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans. Clin Cancer Res (2007) 1.45
Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) (2010) 1.45
Tumor priming enhances delivery and efficacy of nanomedicines. J Pharmacol Exp Ther (2007) 1.44
Transvenous phrenic nerve stimulation in patients with Cheyne-Stokes respiration and congestive heart failure: a safety and proof-of-concept study. Chest (2012) 1.43
Dofetilide enhances the contractility of rat ventricular myocytes via augmentation of Na+-Ca 2+ exchange. Cardiovasc Drugs Ther (2009) 1.41
¹⁸F-FDG-PET and ¹⁸F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol (2012) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Effects of active and passive smoking on the development of cardiovascular disease as assessed by a carotid intima-media thickness examination in patients with type 2 diabetes mellitus. Clin Exp Pharmacol Physiol (2015) 1.38
A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis. J Biol Chem (2004) 1.37
Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation (2008) 1.36
Transposition-driven genomic heterogeneity in the Drosophila brain. Science (2013) 1.35
CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol (2014) 1.34
Chlamydia vaccine candidates and tools for chlamydial antigen discovery. Expert Rev Vaccines (2009) 1.34
Effects of GCK, GCKR, G6PC2 and MTNR1B variants on glucose metabolism and insulin secretion. PLoS One (2010) 1.33
Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma. Tumour Biol (2014) 1.32
Probing alpha-helical and beta-sheet structures of peptides at solid/liquid interfaces with SFG. Langmuir (2005) 1.29
Genome-wide association study identifies three novel loci for type 2 diabetes. Hum Mol Genet (2013) 1.28
Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J (2002) 1.28
A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer. Int J Oncol (2006) 1.27
Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. J Infect Dis (2006) 1.27
Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk: a meta-analysis. World J Gastroenterol (2010) 1.26
Intraperitoneal therapy for peritoneal cancer. Future Oncol (2010) 1.25
Pancreatic cancer: pathobiology, treatment options, and drug delivery. AAPS J (2010) 1.25
The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J (2013) 1.24
NPInter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res (2006) 1.24
Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 are associated with glucose metabolism in the Chinese. PLoS One (2010) 1.23
Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. Blood (2007) 1.23
Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res (2010) 1.23